Ultragenyx Pharmaceutical Inc. RARE
The biggest changes in the 10-K filed Feb 18, 2026, in management's words
10-K, Item 7This fiscal year against the last, and the sentences in the MD&A where management explains each change. Tickdelta picks sentences that name the line, a direction and a cause. It does not write explanations of its own.
Operating margin
Big change, FY to Dec 31, 2025 vs Dec 31, 2024
“for other research and development expenses, a decrease primarily due to decreased staffing and cost efficiencies to support internal manufacturing, and administrative and general support.”
Read it in the 10-K
Revenue
Big change, FY to Dec 31, 2025 vs Dec 31, 2024
“The increase in revenue was driven by higher demand for our approved products.”
Read it in the 10-K
“This increase in Crysvita revenue was primarily due to an increase in the number of patients on therapy.”
Read it in the 10-K
What management said, year by year
The cause given in each 10-K, 2 fiscal years, newest first · MD&A (Item 7)
Each bar is how the line changed that year (from the same 10-K's XBRL). Under it, the sentence in that year's MD&A that names the line, a direction and a cause, word for word. A year with no sentence says so.
Revenue
2 of 2 years explained-
FY 2025 +20.2%
“The increase in revenue was driven by higher demand for our approved products.”
Read it in the FY 2025 10-K“This increase in Crysvita revenue was primarily due to an increase in the number of patients on therapy.”
Read it in the FY 2025 10-K -
FY 2024 +29.0%
“The increase in revenue was driven by higher demand for our approved products.”
Read it in the FY 2024 10-K“Our Crysvita royalty revenue and collaboration revenue in the Profit-Share Territory increased by a net $22.5 million for the year ended December 31, 2024, compared to the same period in 2023; this increase in Crysvita revenue is primarily due to an increase in the number of patients on therapy.”
Read it in the FY 2024 10-K
Operating margin
2 of 2 years explained-
FY 2025 +16.2 pts
“for other research and development expenses, a decrease primarily due to decreased staffing and cost efficiencies to support internal manufacturing, and administrative and general support.”
Read it in the FY 2025 10-K -
FY 2024 +35.4 pts
“for other research and development expenses, an increase of $1.2 million, primarily related to increased staffing to support internal manufacturing, and administrative and general support.”
Read it in the FY 2024 10-K
Changes are computed from the XBRL figures in the same 10-K. Hover a number to see the line item. Open the 10-K
Sources
The Management's Discussion and Analysis (Item 7) of the latest 10-K, quoted word for word; the changes are computed from the same 10-K's XBRL.
Also
Financials: the numbers year by year.
Work with it
Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/RARE/export.csv") into a cell.